Scarica l'app Stockscreener
240.19
1.63%
3.85
Dopo l'orario di chiusura:
240.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$236.34
Aprire:
$235.87
Volume 24 ore:
286.79K
Relative Volume:
0.81
Capitalizzazione di mercato:
$6.72B
Reddito:
$2.58B
Utile/perdita netta:
$-778.69M
Rapporto P/E:
-8.7885
EPS:
-27.33
Flusso di cassa netto:
$223.75M
1 W Prestazione:
+0.01%
1M Prestazione:
+6.47%
6M Prestazione:
-35.83%
1 anno Prestazione:
-14.17%
Intervallo 1D:
$233.10
$243.13
Intervallo di 1 settimana:
$233.10
$255.00
Portata 52W:
$215.38
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Confronta BIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
240.19 | 6.72B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
U.S. Hemoglobinopathy Market 2025-2032: Top Trends & Growth - openPR.com
One Step RT-qPCR Kits Market Top Players- Takara Bio Inc., - openPR.com
Laboratory Proficiency Testing Market Is Booming Worldwide | - openPR.com
Biodetection Market Deep Research 2025-2032 | Bio-Rad - openPR.com
Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report - Yahoo Finance
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Bio-Rad Earnings: Revenue Declines Driven by Weak Academic Research Market; Guidance Lowered - Morningstar
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Call Transcript - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Ra - GuruFocus
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Rad Laboratories | BIO Stock News - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | B - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | BIO Stock News - GuruFocus
Bio-Rad's Steady Business and Stake in Sartorius Driving Long-Term Value - Morningstar
RBC Capital Lowers Price Target for Bio-Rad Laboratories (BIO) | BIO Stock News - GuruFocus
Cell-Based Assays: The Future of Biomedical Breakthroughs - GlobeNewswire Inc.
Bio-Rad (BIO) Target Price Cut by UBS Amid Macroeconomic Concerns | BIO Stock News - GuruFocus
Bio-Rad (BIO) Sees Price Target Reduced by Citi Analyst After Q1 Report | BIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Biosensors Market Future Business Opportunities 2025-2032 | - openPR.com
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket - Yahoo Finance
Biomarker Testing Market: Trends, Growth, and Key Insights 2025 - openPR.com
Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo
The Best Healthcare Stocks to Buy - Morningstar
Bio Rad Laboratories Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bio-Rad Laboratories Reports Q1 2025 Financial Results - TipRanks
Bio-Rad: Q1 Earnings Snapshot - MySA
Bio-Rad Laboratories (BIO) Faces Revenue Challenges Amid Market Headwinds - GuruFocus
Bio-Rad Laboratories Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Bio-Rad Labs exceeds Q1 2025 earnings expectations - Investing.com
Bio-Rad Reports First-Quarter 2025 Financial Results - BioSpace
Bio-Rad Labs beats Q1 estimates, lowers 2025 outlook By Investing.com - Investing.com South Africa
Bio-Rad Labs beats Q1 estimates, lowers 2025 outlook - Investing.com
Bio-Rad Laboratories Expects 2025 Non-GAAP Revenue to Range From 1% Drop to 1.5% Growth Vs. Prior Est 1.5% to 3.5% Gain - marketscreener.com
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates - Yahoo Finance
Bio-Rad (BIO) Revises 2025 Financial Projections | BIO Stock New - GuruFocus
Bio-Rad Reports First-Quarter 2025 Financial Results | BIO Stock News - GuruFocus
BIO Surpasses Q1 Revenue Expectations, Adjusts 2025 Outlook | BI - GuruFocus
BIO-RAD LABORATORIES, INC. SEC 10-Q Report - TradingView
Earnings Flash (BIO) Bio-Rad Laboratories Reports Q1 Revenue $585.4M, vs. FactSet Est of $573.3M - marketscreener.com
Lyme Disease Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
A Preview Of Bio-Rad Laboratories's Earnings - Nasdaq
Molecular Quality Control Market Report: Insights, Analysis & - openPR.com
(BIO) Proactive Strategies - news.stocktradersdaily.com
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins’ Small-Cap Stocks with Huge Upside Potential - MSN
Malaria Diagnostics Market Overall Study Report 2025-2032 | - openPR.com
Biodesix and Bio-Rad Drive Advances in ctDNA-Based Cancer Therapies - Technology Networks
Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile? - MSN
Biopharmaceutical Processing Equipment and Consumables - openPR.com
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.62%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):